Risperdal News and Research

RSS

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes, Inc. today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010.

7 Aug 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010

Sermo Category Report: About 30% of patients suffer from depression

Sermo, the world's largest online community for physicians, today announced a Sermo Category Report titled Antidepressant Treatment Behaviors. The report surveyed more than 200 primary care physicians and covers a variety of topics including product choice drivers, treatment paths, referring habits, and overall issues in depression management.

6 May 2010

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the first quarter of 2010, an increase of 4.0% as compared to the first quarter of 2009. Operational results declined 0.1% and the positive impact of currency was 4.1%.

21 Apr 2010

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug.

23 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

2 Dec 2009

Behavior problems in children with autism can be reduced with a training program for parents

The serious behavior problems that can occur in children with autism and related conditions can be reduced with a treatment plan that includes medication combined with a structured training program for parents, according to Yale University researchers and their colleagues.

26 Nov 2009

Health care jobs plentiful but tough to get

While health care jobs are plentiful, "getting one is hard work," The Associated Press/The News-Sentinel reports. "Many people who have lost jobs to the recession may find a cure for unemployment in the health care field," and the demand for nurses, specialists and technicians is strong

4 Nov 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S. history.

3 Sep 2009

St. Petersburg Times examines decline in antipsychotic drug prescriptions for Florida children

St. Petersburg Times recently examined how since the Florida Medicaid program last year began requiring physicians to receive approval before prescribing antipsychotic drugs to children younger than age six, the number of prescriptions for children in that age group has dropped by nearly 75%, according to new data from the Florida Agency for Health Care Administration.

31 Mar 2009

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Antipsychotic drugs, such as olanzapine (Zyprexa), risperidone (Risperdal) and quetiapine (Seroquel), are commonly used to treat psychotic disorders like schizophrenia, but also bipolar disorder and even behavioral problems related to dementia.

29 Mar 2009

Mylan receives FDA approval for generic version of Risperdal

Mylan Inc today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone Tablets USP, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.

16 Sep 2008

Study questions use of newer antipsychotic drugs in children

A new study has found that older antipsychotic drugs are as effective as newer ones for some children.

16 Sep 2008

Older antipsychotic drugs as effective, offer fewer side effects in children than newer drugs, study finds

The two most frequently prescribed antipsychotic drugs for children and adolescents offer no additional benefit and are more likely to cause side effects than an older, less costly medication, according to a National Institute of Mental Health study published on Monday, the New York Times reports.

16 Sep 2008

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

15 Sep 2008

FDA approves generic Risperidone for the treatment of schizophrenia, bipolar disorder

The U.S. Food and Drug Administration today approved the first generic versions of Risperdal (risperidone) tablets. Risperdal is an antipsychotic drug used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions.

1 Jul 2008

Risperdal News and Research

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Sermo Category Report: About 30% of patients suffer from depression

Johnson & Johnson' first-quarter 2010 sales increase 4.0% to $15.6 billion

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Behavior problems in children with autism can be reduced with a training program for parents

Health care jobs plentiful but tough to get

Johnson & Johnson announces financial results for the third quarter of 2009

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

St. Petersburg Times examines decline in antipsychotic drug prescriptions for Florida children

Add-on treatment may reduce treatment-associated weight gain caused by antipsychotic treatments

Mylan receives FDA approval for generic version of Risperdal

Study questions use of newer antipsychotic drugs in children

Older antipsychotic drugs as effective, offer fewer side effects in children than newer drugs, study finds

Newer atypical antipsychotic medications no better than older drug in treating child and adolescent schizophrenia

FDA approves generic Risperidone for the treatment of schizophrenia, bipolar disorder

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News